Pharma Focus Asia
KP - Sustainable Packaging Solutions

CordenPharma and Moderna collaborate in obtaining the coronavirus vaccine

Friday, May 29, 2020

CordenPharma , a full-service contract manufacturing and development (CDMO) organization for the supply of APIs, Drug Products and Pharmaceutical Packaging, announces the signing of a modification to its agreement to with existing manufacturing Modern, Inc., a clinical phase biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The extension allows CordenPharma to manufacture large-scale volumes of Moderna lipid excipients for use in manufacturing the Moderna vaccine candidate (mRNA-1273) against the new coronavirus (SARS-CoV-2).

Under the terms of the agreement, the companies will expand their supply relationship by expanding the manufacturing agreement originally signed in 2016 between Moderna and  CordenPharma Switzerland . The amended agreement now includes  CordenPharma Chenôve  (France) and  CordenPharma Colorado  (USA) for the manufacture of larger-scale volumes of lipids, while drawing on CordenPharma Switzerland's long-standing reputation as a leader in specialized lipid manufacturing . The expanded agreement will begin immediately to quickly meet Moderna's growing demand in the coming months, with an emphasis on securing its future long-term supply.  

Juan Andres , director of Technical Operations and Quality at Moderna, commented: "We are delighted to extend our agreement with CordenPharma. This expansion will increase the supply of lipid excipients used to manufacture our mRNA products. We appreciate CordenPharma's global presence and experience of CDMO as we scale manufacturing of mRNA-1273 ".

Dr Michael Quirmbach , CEO and Chief Executive Officer of CordenPharma, said: "We are delighted to extend our long-term agreement to help support Moderna by leveraging our strong global network of GMP manufacturing facilities in Europe and the United States to supply the immediate need for lipid excipients for your coronavirus vaccine. We hope Moderna's technology will positively impact COVID-19 sufferers worldwide, and we are proud to contribute to the industry as a whole. "

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelEquinix accelerated medical research...Asia Healthcare Week 2024CPHI Korea 2024Thermofisher - Antibody Therapeutic PolishingCHEMICAL INDONESIA 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024INALAB 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?